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For more than 40 years, observational epidemiologic studies
have consistently documented that individuals with elevated
serum total cholesterol are at increased risk for a first
coronary heart disease (CHD) event (1–4). In general,
clinical data indicate that CHD risk is 2% to 3% lower for
each 1% decrease in total cholesterol concentration (1).
Early clinical trials (5–9) demonstrated that drug-induced
reductions in serum cholesterol would prevent first CHD
events, yet these successes were plagued by uncertainties
about the effect of such therapy on noncardiovascular
morbidity and mortality. Because of these uncertainties and
the modest lipid-modifying efficacy of the bile-acid-
sequestrant and fibric-acid-derivative interventions used,
many cardiologists and, hence, most clinicians did not
embrace cholesterol-lowering drug therapy for primary pre-
vention of CHD except in patients with severe genetic lipid
disorders or high short-term risk for disease. However, the
question of whether cholesterol lowering is beneficial has
now been very clearly addressed with the advent of the
HMG-CoA reductase inhibitors (statins), which have made
possible very substantial reductions in low-density lipopro-
tein (LDL) cholesterol concentrations in clinical usage. In
1995 the West of Scotland Coronary Prevention Study
(WOSCOPS) reported significant reductions in rates of
first coronary events over five years with pravastatin therapy
in middle-aged men with high baseline cholesterol concen-
trations (10). Most important, therapy was associated with
no adverse noncardiovascular effects compared with placebo.
Recently, the results of the five-year Air Force/Texas
Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS) of lovastatin in a cohort of asymptomatic men
and women extended the coronary benefit of statin therapy
in primary prevention to healthier individuals with choles-
terol concentrations comparable with the national average
(11).
In current adult practice guidelines from the U.S. Na-
tional Cholesterol Education Program (NCEP) (12), can-
didates for lipid-lowering drug therapy in primary preven-
tion are those at high risk for a CHD event in the near term
(Table 1). High risk may be conferred by LDL cholesterol
elevation alone when the average value is 190 mg/dL or
higher or by LDL cholesterol of 160 mg/dL or higher in the
presence of at least two other major risk factors for CHD.
Patients with less severe LDL cholesterol elevations but
with other risk factors (e.g., type 2 diabetes mellitus or a
family history of premature CHD) may also be candidates
in the NCEP algorithm. It is of great interest whether the
AFCAPS/TexCAPS results, which extend the benefit of
lipid-lowering drug therapy to a large segment of the
population at risk for CHD, might prompt reconsideration
of the NCEP action limits.
EARLY PRIMARY-PREVENTION DRUG TRIALS
The first major randomized clinical trial to assess whether
drug treatment of hyperlipidemia would reduce rates of first
coronary events was the five-year World Health Organiza-
tion trial of clofibrate, a double-blind study that enrolled
15,745 men aged 30 to 59 years (5). The 9% reduction in
cholesterol from baseline by clofibrate was associated with a
significant 25% decrease in the rate of nonfatal myocardial
infarction compared with placebo and a 20% reduction in all
coronary events. However, there was a 47% excess of
mortality during treatment in the clofibrate group although
the difference was not significant when corrected for age at
death (6,7). Excess mortality was reduced to 5% in eight
years of follow-up after treatment ended (7). No particular
disease accounted for the overall excess, and no causal link
with clofibrate has been found. The mortality findings have
remained a subject of debate for 20 years and have led to
clofibrate’s being used very little in the U.S.
The results of the landmark Lipid Research Clinics
Coronary Primary Prevention Trial (LRC-CPPT), which
were published in 1984 (8), are considered the first major
proof of the lipid-lowering hypothesis with active drug
intervention. In this randomized, double-blind study, 3,806
asymptomatic men aged 35 to 59 years with total cholesterol
of 265 mg/dL or greater (type II hyperlipidemia) received
either dietary modification and cholestyramine or diet and
placebo. Over seven years, resin therapy reduced mean total
and LDL cholesterol values 8% and 13% more than placebo,
and the rate of CHD death or nonfatal myocardial infarc-
tion was 19% lower (p , 0.05) in the resin-treated group.
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All-cause mortality rate, which the trial was not designed to
assess, was reduced by only 7%, reflecting an nonsignificant
increase in noncardiovascular deaths. Of the causes of death,
11 were from accidents and violence in the drug group,
compared with four in the placebo group. However, no
convincing evidence has ever been presented that the excess
deaths from accidents and violence were in any way related
to the nonabsorbable resin (14). The lipid-lowering efficacy
of cholestyramine in the LRC-CPPT was limited by the
poor tolerability of the bile acid sequestrant. Sixty-eight
percent of the patients reported at least one gastrointestinal
side effect in the first year of treatment, and the average daily
dose taken was only about 14 g/day although 24 g/day was
prescribed.
The Helsinki Heart Study (HHS) followed in 1987 and
showed a significant 34% reduction (p , 0.02) in CHD
incidence (cardiac death plus myocardial infarction) after
five years of diet plus gemfibrozil therapy compared with
diet plus placebo (9). The trial enrolled 4,081 asymptomatic
men aged 40 to 55 years with non-high-density lipoprotein
(non-HDL) cholesterol of 200 mg/dL or greater. Non-
HDL cholesterol includes LDL, intermediate-density li-
poprotein (IDL) and very-low-density lipoprotein (VLDL)
cholesterol values and is a measure of all lipoproteins that
contain apolipoprotein B. Lipid changes in the gemfibrozil
group versus placebo were: total cholesterol 211%, LDL
cholesterol 210%, serum triglyceride 243% and HDL
cholesterol 111%. Non-HDL cholesterol was reduced by
14%. As in the LRC-CPPT, there was a nonsignificant,
greater number of deaths with drug therapy due to accidents
and violence (10 vs. 4). There were also more deaths from
intracranial hemorrhage (five vs. one), although, again, the
difference was not statistically significant. As in the LRC-
CPPT, these deaths could not be directly linked to drug
therapy. Between the LRC-CPPT and HHS, 5 of the 8
suicides were trial dropouts, 2 were homicide victims and,
among the 10 subjects who died of an accident, 2 were trial
dropouts, 3 had high blood alcohol at autopsy and another
3 had a history of psychiatric symptoms or treatment (14).
A meta-analysis of early primary-prevention trials
showed that a 10% reduction in cholesterol led to 25%, 12%
and 22% reductions in nonfatal, fatal and all myocardial
infarctions (15). A subsequent meta-analysis added a non-
significant 8% reduction in total mortality (16). Neverthe-
less, concerns about noncardiovascular mortality in the
WHO trial, LRC-CPPT and HHS led to many analyses
and commentaries about the safety of cholesterol lowering
(17,18). Several suggested that drug treatment to lower
cholesterol in primary prevention be reserved for only the
highest-risk individuals or even that cholesterol screening be
restricted (19,20). The Adult Treatment Panel of the
NCEP, however, consistently held, as did many other
experts (21,22), that the weight of evidence supporting
CHD benefit by lipid-lowering therapy, including pharma-
cotherapy, overshadowed any noncardiovascular risk. How-
ever, the NCEP algorithm endorses the most aggressive
lipid modification in secondary prevention where the risk
for recurrent disease is highest, and where primary preven-
tion remained a much lower priority than secondary pre-
vention (12). At the time the current NCEP adult guide-
lines were issued in 1993, there was a growing body of
evidence demonstrating angiographic lesion benefit in pa-
tients with established atherosclerotic disease (23).
STATIN PRIMARY-PREVENTION TRIALS
In WOSCOPS, which enrolled 6,595 men aged 45 to 64
years who had no history of myocardial infarction, prava-
statin therapy with background diet doubled the LDL-
cholesterol lowering seen in earlier primary-prevention
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Table 1. Risk Status in Patients Without Known
Atherosclerotic Disease
High Risk Moderate Risk
LDL-C $190 LDL-C 190 to 220 in young
adult men (,35 years) and
premenopausal women
with no other risk*
or
LDL-C between 160 and
190 1 $2 other CHD
risk factors
or
LDL-C between 160 and
190 1 ,2 other CHD
risk factors
or
LDL-C between 130 and
160 1 Risk of Severe
Degree, e.g., type 2
diabetes mellitus or
heavy cigarette smoking
or
LDL-C between 130 and
160 1 $2 other CHD
risk factors
*In young men ,35 yr and premenopausal women with LDL-C in the range 160 to
220 mg/dL and no other risk factors, drug therapy should be delayed in favor of
lifestyle intervention. For most young adult men and premenopausal women, drug
therapy should be considered when LDL-C is very high (.220 mg/dL) or multiple
other risk factors are present. Note: All LDL-C values are mg/dL. Source: Data from
Jones et al. (13).
CHD 5 coronary heart disease; LDL-C 5 low-density lipoprotein cholesterol.
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trials. The 26% reduction was associated with a significant
31% reduction in definite coronary events (CHD death or
nonfatal myocardial infarction) at five years compared with
placebo. All-cause mortality rate was reduced by 22%—the
reduction just missing statistical significance (p 5 0.051).
Noncardiovascular disease end points were not changed,
including violent deaths and cancers, between active treat-
ment and placebo. A divergence in CHD effect between the
pravastatin and placebo groups began to emerge as soon as
six months after the beginning of the trial although the
difference was not significant at that date (10). Pravastatin
therapy was well tolerated.
Coronary risk in WOSCOPS was related to lipid con-
centrations at baseline, namely, LDL cholesterol and tri-
glyceride above median and HDL cholesterol below median
(treatment also reduced triglyceride by 12% and increased
HDL by 5%). Enrollment in WOSCOPS required LDL
cholesterol of at least 155 mg/dL during two screening
visits with at least one value $174 mg/dL and one value
#232 mg/dL and fasting triglyceride no higher than 530
mg/dL. Mean baseline LDL cholesterol was 192 mg/dL,
and, although WOSCOPS was begun before development
of current NCEP guidelines, 77% of its patients fell within
NCEP categories for consideration of lipid-lowering phar-
macotherapy, given that all had received dietary therapy
(24). The NCEP recommendation of using pharmacother-
apy in high-risk patients without prior myocardial infarction
was validated, and the efficacy and safety of the statin
therapy catapulted this class of agent to the forefront of
primary prevention.
Despite the positive results of WOSCOPS, several ques-
tions remained. All four primary-prevention drug treatment
trials included only middle-aged men; none included men
aged 65 or older or women. The focus of intervention was
in individuals with substantial elevations in cholesterol, as
demonstrated by the mean baseline LDL-cholesterol values
of the LRC-CPPT (204 mg/dL), HHS (188 mg/dL) and
WOSCOPS (192 mg/dL) and the median total cholesterol
value of the WHO clofibrate group (247 mg/dL) (Fig. 1).
For most patients, total cholesterol of 240 mg/dL corre-
sponds roughly to LDL cholesterol of 160 mg/dL (12).
Also, because conclusive findings on overall mortality were
not reported, some still voiced concern about the safety of
lowering cholesterol with medication.
The AFCAPS/TexCAPS results (11) shed important
light on several of these issues. Indeed, a number of features
of the trial distinguish the study from earlier primary-
prevention trials. Of the trial’s 6,605 subjects, 997 were
women and 1,416 were aged 65 to 73 years. Mean
baseline total and LDL cholesterol values were only 221 and
150 mg/dL—comparable with values in the 51st and 60th
percentiles of the third National Health and Nutrition
Examination Survey (NHANES III: 1988–1994) reference
population (Fig. 1) (25).
In WOSCOPS, a small percentage of patients had a
history of angina pectoris according to the Rose question-
naire (5%) or intermittent claudication (3%), but the
AFCAPS/TexCAPS participants had no history, signs or
symptoms of definite myocardial infarction, angina, claudi-
cation, cerebrovascular accident or transient ischemic at-
tacks. As noted, total and LDL cholesterol values were in
the average range for the U.S. population (enrollment
criteria 180 mg/dL to 264 mg/dL and 130 mg/dL to
190 mg/dL, respectively, with triglyceride #400 mg/dL). In
addition, participants had reduced HDL cholesterol: a mean
of 36 mg/dL in men and 40 mg/dL in women (16th and
25th NHANES III percentiles; enrollment criteria #45 and
#47 mg/dL). Other enrollment criteria included age 45 to
73 in men and age 55 to 73 and postmenopausal status in
women (among whom about 30% were taking hormone
replacement therapy). Also, if necessary, lovastatin dosage
was titrated from 20 mg/day to 40 mg/day to achieve a
target LDL cholesterol goal of 110 mg/dL, reflecting more
closely the usual clinical practice of treating patients with
the minimum effective dosage of drug.
Compared with baseline values, lovastatin (mean dosage,
30 mg/day) with diet background reduced LDL cholesterol
by 25% (to 115 mg/dL), increased HDL cholesterol by 6%
and decreased triglyceride by 15%. At five years, coronary
event rates significantly reduced by active treatment in-
cluded first acute major coronary event (unstable angina,
myocardial infarction, and sudden cardiac death, 237%),
fatal or nonfatal myocardial infarction (240%), unstable
angina (232%) and revascularization (233%). In each of
these end point categories, a difference between the drug
and placebo groups was seen in the first year and continued
throughout the remainder of the trial. There were fewer
primary end point events in lovastatin-treated women versus
placebo (7 vs. 13), although this difference was not signifi-
cant. The effect of treatment on first acute coronary event
Figure 1. Baseline lipid values from major primary-prevention
trials in comparison with 50th percentile values from the National
Health and Nutrition Examination Survey (NHANES) III.
AFCAPS/TexCAPS 5 Air Force/Texas Coronary Prevention
Study; HDL-C 5 high-density lipoprotein cholesterol; HHS 5
Helsinki Heart Study; LDL-C 5 low-density lipoprotein choles-
terol; LRC-CPPT 5 Lipid Research Clinics Coronary Primary
Prevention Trial; Total-C 5 total cholesterol; WOSCOPS 5
West of Scotland Coronary Prevention Study. { 5 AFCAPS/
TexCAPS; E 5 HHS;  5 LRC-CPPT; w 5 NHANES III,
50th percentile; h 5 WOSCOPS.
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was consistent for patients above and below the median age
by sex (57 years in men and 62 years in women) as well as
for other predefined subgroups, such as smokers and those
with hypertension. The AFCAPS/TexCAPS suggested
that the benefit in women and older participants was
comparable with that observed in the overall cohort. Clin-
ical benefit was across all tertiles of baseline LDL choles-
terol and HDL cholesterol without evidence of a threshold
effect. Lovastatin therapy was well-tolerated, and there was
no difference in noncardiovascular or total mortality rate
between the drug and placebo groups.
Thus, AFCAPS/TexCAPS is the first primary-
prevention trial of lipid modification to demonstrate coro-
nary risk reduction in generally healthy men and women
without clinical evidence of atherosclerotic disease and with
only average cholesterol but below-average HDL choles-
terol concentrations. In contrast to WOSCOPS, only 17%
of the AFCAPS/TexCAPS participants would have met
current NCEP criteria for drug therapy (11).
COST-EFFECTIVENESS OF LIPID-LOWERING
TREATMENT IN PRIMARY PREVENTION
The AFCAPS/TexCAPS investigators calculate that using
lovastatin to treat 1,000 men and women meeting the study
criteria for 5 years would prevent approximately 12 myocar-
dial infarctions, 7 presentations of unstable angina and 17
coronary revascularization procedures (11). However, the
large pool of potential patients (approximately six million
Americans meet the study’s age and lipid criteria but would
not qualify for drug treatment according to current NCEP
guidelines) raises important questions about the cost of
implementing such treatment. Previous analyses of statin
trials have reported that such therapy is cost-effective in
secondary prevention (26–29). Analysis of WOSCOPS
data has suggested that the cost-effectiveness of primary
prevention improves as the number of CHD risk factors per
subject increases and, hence, as their near-term risk for
experiencing a CHD event increases (30).
A recent coronary prediction model based on Framing-
ham data relies on the concept of risk factor clustering to
predict the patient population most likely to benefit from
primary-preventive treatments (31). An accompanying
American Heart Association statement (32) emphasizes the
value of this approach and supports the NCEP Adult
Treatment Panel guidelines, which also adjust the decision
to treat and the intensity of treatment according to the
number and severity of risk factors. Such an analysis may be
of value with the AFCAPS/TexCAPS population to ascer-
tain which patient characteristics and risk factor clusters are
most cost-effective for statin therapy in primary prevention.
CLINICAL IMPLICATIONS OF THE STATIN TRIALS
For patients, primary-care physicians and cardiologists, the
results of WOSCOPS and AFCAPS/TexCAPS provide
strong evidence for the benefits of primary prevention
through lipid-regulating treatment, as well as reassurance
concerning the safety of statin therapy. In particular, the
AFCAPS/TexCAPS data extend the benefits to a large
segment of the population at risk for a first CHD event.
Both studies confirm the NCEP guidelines for high-risk
patients without clinically evident atherosclerotic disease
and underscore the necessity of measuring HDL cholesterol
in clinical assessment. Future economic evaluation of the
AFCAPS/TexCAPS trial will provide valuable information
concerning the cost-effectiveness of treatment in selected
patient groups. According to estimates based on phase 2
NHANES III data (1991–1994), only 1.4 million, or 6.6%,
of 21.1 million U.S. adults who are currently eligible for
cholesterol-lowering drug therapy by NCEP guidelines are
receiving such therapy, including 14% of those eligible in
secondary prevention and 4% of those eligible in primary
prevention (33). Sixty-five percent of diet- or drug-eligible
adults are receiving no therapy of any kind. These statistics
are discouraging, especially in light of the substantial evi-
dence demonstrating the benefit and general safety of such
treatment, and demand continued vigilance in physician
efforts to reverse the toll of atherosclerotic disease.
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